Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

SparX Biopharmaceutical Corp. announced today that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-in-Progress ...

Vantage Market Research report examines the Antibody Drug Conjugates (ADCs) market, forecasting trends and dynamics from 2025 ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company continues to expand its capabilities in artificial ...

Collaboration combines BigHat's AL/ML-powered Milliner™ platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies.

CSPC PHARMA (01093.HK) announced that the Investigational New Drug (IND) application for SYS6041 (Antibody-Drug Conjugate) ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...